Status:
WITHDRAWN
Risk Factors for Allo-immunization in Sickle Cell Disease
Lead Sponsor:
Hanane EL KENZ
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
Brief Summary
Sickle cell patients have a high prevalence of alloimmunization. This high rate of alloimmunization can be partially explained by the existence of an antigenic difference between the predominantly Cau...
Eligibility Criteria
Inclusion
- \- Sickle cell disease patients (HbSS genotype) with a history of blood transfusions within the CHU Brugmann and the Queen Fabiola University Hospitals.
Exclusion
- \- None
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2018
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03401125
Start Date
February 1 2018
End Date
July 1 2018
Last Update
July 26 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020
2
HUDERF
Brussels, Belgium, 1020